How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,794 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

7641. Umbilical cord care in premature infants: the effect of two different cord-care regimens (salicylic sugar powder vs chlorhexidine) on cord separation time and other outcomes. (Abstract)

or from the umbilicus if the cord was already sloughed. Six weeks after birth, during hospitalization or during a follow-up visit if already discharged, all infants had a medical examination to check the umbilicus area. Cord separation time, changing of the programmed cord-care regimen, death, omphalitis, sepsis, cord bleeding, nurses' opinion on treatments efficacy, and UC colonization were measured.The cord separation time was significantly lower in infants who were treated with salicylic sugar (...) (98%) than with the chlorhexidine treatment (67%), notwithstanding a more frequent occurrence of slight cord scar bleeding in the salicylic sugar group (7.8%) than in the chlorhexidine group (4%). The rate of negative umbilical swabs was significantly higher in infants treated with salicylic sugar powder (73.1%) than with chlorhexidine (53%).In neonatal intensive care units and neonatal special care units of developed countries, salicylic sugar powder can be used effectively and safely for UC care

2003 Pediatrics Controlled trial quality: uncertain

7642. Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia

Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000582113 RUH-PHO-0514-0306 First Posted: February 8, 2008 Last Update Posted: February 17, 2009 Last Verified: February 2008 Keywords provided by National Cancer Institute (NCI): colon cancer rectal cancer Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms (...) Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Folic Acid Hematinics Vitamin B Complex Vitamins Micronutrients Nutrients Growth Substances Physiological Effects of Drugs

2008 Clinical Trials

7643. Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis

: UC, requiring immediate surgical, endoscopic, or radiological intervention; including massive haemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or peri-anal abscesses) or toxic colon, history of large bowel surgery, history of serious infections, positive stool cultures, including Clostridium difficile, significant organ dysfunction, pregnancy, nursing mothers, or women of childbearing potential without appropriate use of contraceptives, treatment with: an altered (...) Last Verified: March 2012 Keywords provided by AM-Pharma: Ulcerative Colitis UC moderate severe LPS Alkaline Phosphatase AP BIAP Mucositis Additional relevant MeSH terms: Layout table for MeSH terms Colitis Ulcer Colitis, Ulcerative Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases

2008 Clinical Trials

7644. Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Inclusion criteria: Normal, healthy gastrointestinal tract (no small bowel mucosal breaks at Day 14 according to endoscopic data No history of GI ulcers, bleeding or surgery, or complete or partial stenosis of the small intestine Willing not to drink any alcohol during study period Exclusion Criteria: Exclusion criteria: Has established delayed gastric emptying or diabetic gastroparesis Has active (...) : A3191071 First Posted: March 21, 2008 Last Update Posted: April 7, 2008 Last Verified: March 2008 Keywords provided by Pfizer: Bowel Disease Additional relevant MeSH terms: Layout table for MeSH terms Intestinal Diseases Inflammatory Bowel Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Ibuprofen Celecoxib Omeprazole Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects

2008 Clinical Trials

7645. Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases

gastrointestinal ulcer bleeding under ASA, indications exist that a continuation of treatment with lower-dose ASA combination therapy plus a PPI (esomeprazole) results in a higher patient-relevant benefit than a switch to clopidogrel. There is no evidence available that in patients who experienced a vascular event under ASA, a switch to clopidogrel therapy results in an additional patient-relevant benefit. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin /therapeutic use; Platelet (...) has been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases. Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aims of this evaluation were: 1. the comparative evaluation of the benefits and harms of clopidogrel and ASA as antiplatelet monotherapy for secondary prevention in patients

2006 Health Technology Assessment (HTA) Database.

7646. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. (Abstract)

A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. The introduction of an effective antiplatelet therapy with aspirin and ticlopidine after the placement of coronary-artery stents has decreased the risk of thrombotic stent occlusions (TSO) and hemorrhagic complications. However, the use of ticlopidine is limited by hematological and gastrointestinal adverse effects. The safety and efficacy of clopidogrel after (...) documented TSO, or nonfatal myocardial infarction within 30 days. The primary noncardiac endpoint was defined as noncardiac death, stroke, severe peripheral vascular or hemorrhagic events, or any adverse event resulting in discontinuation of study medication. Cardiac events occurred in 17 patients [11 (3.1%) with clopidogrel and 6 (1.7%) with ticlopidine (P=0.24)]. The primary noncardiac endpoint was observed in 16 patients (4.5%) assigned to receive clopidogrel versus 33 patients (9.6%) assigned

2000 Circulation Controlled trial quality: uncertain

7647. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. (Abstract)

gastrointestinal bleeding were 0.49 vs 0.71%; p < 0.05. Overall, there were significantly fewer gastrointestinal adverse events with clopidogrel than with aspirin (27.1 vs 29.8%; p < 0.001), with less abdominal pain, dyspepsia, constipation, or peptic, gastric, or duodenal ulceration with clopidogrel. Diarrhoea was significantly more common in the clopidogrel group (4.46 vs 3.36%; p < 0.001), although the incidence of severe diarrhoea (0.23 vs 0.11%) was low and was not significantly different between groups (...) Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. The objective of this study was to provide a comprehensive comparison of the long term safety and tolerability of clopidogrel, a new adenosine diphosphate (ADP) receptor antagonist that inhibits platelet activation induced by ADP, and aspirin (acetylsalicylic acid).The study population comprised

1999 Drug safety : an international journal of medical toxicology and drug experience Controlled trial quality: uncertain

7648. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). (Abstract)

Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Low-dose aspirin (acetylsalicylic acid) therapy has been shown to reduce the risk of vascular events and there is increasing evidence of its potential to reduce the rate of cognitive decline in the elderly. Adverse effects including gastrointestinal and intracranial haemorrhage may offset (...) these benefits. The balance of risks versus benefits of aspirin for the primary prevention of cardiovascular disease and vascular dementia has not been established in the elderly. There is clearly a need to conduct a study in family practice to investigate whether routine use of low-dose aspirin for the primary prevention of cardiovascular disease and vascular dementia in the elderly is beneficial or harmful. Aspirin in reducing events in the elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin

2003 Drugs & Aging Controlled trial quality: uncertain

7649. Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic (...) colonogram or MRI or PET or Ultrasound) within 16 months prior to randomization Written informed consent Exclusion Criteria Pre-existing Familial adenomatous polyposis, inflammatory bowel disease or ulcerative colitis Active gastritis or active peptic ulcer History of continuous daily use of PPI more than 1 year prior to consent Gastrointestinal bleeding within the past one year Haemorrhagic diathesis (i.e. haemophilia) Uncontrolled hypertension (untreated systolic blood pressure > 160 mmHg, or diastolic

2007 Clinical Trials

7650. Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function. (Abstract)

, 24 (12), 1993-2000, Bloomfield, E.; Rady, M.; Popovich, M.; Esfandiari, S.; Bedocs, N. The use of diaspirin crosslinked hemoglobin (DCLHb 1996, 95, (3A), A220.]. We conducted a randomized prospective open-label trial of DCLHb and packed red blood cells (PRBCs) in high-blood loss surgical patients to show the effect of 750 ml DCLHb (approximately 1000 mg/kg) on selected indices of organ function.After institutional approval, 24 patients scheduled to undergo elective orthopedic or abdominal surgery (...) Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function. The safety of the hemoglobin based oxygen carrier diaspirin crosslinked hemoglobin (DCLHb) has been reported only in the low (50-200 mg/kg) dose range [Przybelski. R.J.; Daily, E.K.; Kisicki, J.C.; Mattia-Goldberg, C.; Bounds, M.J.; Colburn, W.A. Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution. Crit. Care Med. 1996

2002 Artificial cells, blood substitutes, and immobilization biotechnology Controlled trial quality: uncertain

7651. Antiplatelet prophylaxis. Consider the protective effect of blood loss from the gut. (Full text)

Antiplatelet prophylaxis. Consider the protective effect of blood loss from the gut. 8148719 1994 05 06 2018 11 13 0959-8138 308 6929 1994 Mar 05 BMJ (Clinical research ed.) BMJ Antiplatelet prophylaxis. Consider the protective effect of blood loss from the gut. 651-2 Sullivan J L JL eng Comment Letter England BMJ 8900488 0959-8138 R16CO5Y76E Aspirin AIM IM BMJ. 1994 Jan 22;308(6923):235-46 8054013 Aspirin therapeutic use Gastrointestinal Hemorrhage chemically induced Humans Myocardial

1994 BMJ : British Medical Journal PubMed abstract

7652. Is there any evidence that taking aspirin is useful in preventing colon cancer, especially in patients with a family history of colon cancer?

history of colon cancer? We found two large scale large scale studies, both published this year. The Lancet’s article “Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies” [1] concluded: “Use of 300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years, which is consistent with findings from observational studies. Long (...) of Oxford, United Kingdom, and lead author of the study, told Medscape that he agrees with this caution about the general population. Overall from the studies of aspirin use in healthy individuals for the primary prevention of cardiovascular disease, the benefit of aspirin is more or less outweighed by the risk of bleeding (mainly in the gastrointestinal tract, but also in the brain), he noted. However, Dr. Rothwell would argue for use of aspirin to prevent colorectal cancer in certain high-risk

2007 TRIP Answers

7653. Comparison Between Two Endoscopic Treatments of Bleeding Internal Hemorrhoids:Band Ligation and Electrocoagulation Probe

: March 7, 2008 Last Verified: May 2001 Keywords provided by University of California, Los Angeles: Internal hemorrhoids Rubber band ligation Bipolar coagulation Additional relevant MeSH terms: Layout table for MeSH terms Hemorrhoids Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Vascular Diseases Cardiovascular Diseases (...) consent Exclusion Criteria: The patient was uncooperative or could not return for routine outpatient follow-up Severe or end-stage co-morbid illness Prior endoscopic or surgical treatment of hemorrhoids within the past 6 months Ongoing need for anticoagulation therapy or high doses of aspirin or non-steroidal antiinflammatory agents Presence of severe rectal pain Recently thrombosed internal or external hemorrhoids Anal stricture,fissure, fistula,or abscess Rectal carcinoma or bleeding distal colonic

2008 Clinical Trials

7654. A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Recent or planned future major surgery which will result in prolonged immobilization during the study period Presence or history of severe hepatic disease or liver tumors Known or suspected estrogen-dependent neoplasm Vaginal bleeding of unknown etiology Any cigarette smoking and age over 35 years Contraindications to nonsteroidal anti-inflammatory use, such as presence or history of: Gastrointestinal ulcer disease Renal insufficiency or failure Aspirin-induced asthma or hypersensitivity reaction (...) into the treatment of irregular uterine bleeding caused by progestin only contraception . One treatment for progestin-induced irregular bleeding is the administration of nonsteroidal anti-inflammatory agents (NSAIDs). A 1999 study showed a significant decrease in the number of bleeding days in women using the levonorgestrel sub-dermal implant randomized to mefenamic acid 500 mg compared to placebo . A 2004 study found a 50% reduction in bleeding in depot medroxyprogesterone (DPMA) users randomized to mefenamic

2008 Clinical Trials

7655. Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

: blood transfusion Not Applicable Detailed Description: Liver cirrhosis is associated with dysregulation of the coagulation system resulting in an increased bleeding tendency in cirrhotic patients. The treatment approach to offset these abnormalities may involve transfusion with fresh frozen plasma (FFP) and platelets. Fluid overload may become a concern as the large amount of FFP (10-20mls/kg or >1,500ml) required to achieve the hemostatic effect could be contraindicated in some patients (...) by: Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood products in preventing bleeding after teeth extraction in persons with severe liver disease being evaluated for liver transplant. Condition or disease Intervention/treatment Phase Liver Cirrhosis Coagulopathy Drug: Desmopressin Biological

2008 Clinical Trials

7656. Uterine Artery Occlusion for Fibroid Related Bleeding

Frame: 6, 12 and 24 months ] Mean improvement in UFS-QOL Symptom Severity and HRQL transformed scores. [ Time Frame: 6, 12 and 24 months ] Mean HRQL subscales. [ Time Frame: 6, 12 and 24 months ] Percentage of subjects with reduction of 50% or greater in Pictorial Blood Loss Assessment Chart (PBLAC) score. [ Time Frame: 6 and 12 months ] Mean change in PBLAC scores. [ Time Frame: Baseline to 6 and 12 months ] Percentage of subjects with decrease in fibroid load based on independent MRI review (...) inflammatory disease Pelvic mass outside the uterus other than uterine fibroids Any current acute or chronic systemic infection or localized pelvic infection, including a urinary tract infection Use of Gonadotropin-Releasing Hormone (GnRH) agonist, danozol or mifepristone within 6-months prior to the start of the study procedure Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), or have an underlying bleeding disorder Unsuitable for MRI examination (e.g. severe

2007 Clinical Trials

7657. Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib

was 0% in the esomeprazole group and 8.9% in the placebo group (difference, 8.9 percentage points; 95% confidence interval for the difference, 4.1 to 13.7; P=0.0004). During follow-up, 16.1% of patients in the esomeprazole group and 15.4% in the placebo group used low-dose aspirin. Among patients who did not use aspirin, the cumulative incidence of recurrent ulcer bleeding was 0% in the esomeprazole group and 7.1% in the placebo group (difference, 7.1 percentage points; 95% confidence interval, 2.4 (...) , Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor Study Start Date : August 2002 Study Completion Date : June 2005 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : ulcer rebleeding over period of 13 months Secondary Outcome Measures : stroke or cardio-vascular events Eligibility Criteria

2006 Clinical Trials

7658. A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery

(hemodynamically stable and non-coagulopathic) procedures: bowel and colon resections, retroperitoneal dissections/resections, and procedures involving the resection of any solid abdominal organ such as a splenectomy, liver resection, nephrectomy, splenorrhaphy, and pancreatectomy. Bleeding sites evaluated may include soft tissues (e.g. bowel mesentery, adhesions, lymph node beds, sacral venous plexus, etc.) and parenchymal organ bleeds (cut surface of resected liver, spleen, etc., excluding cut surface (...) available for: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Success in achieving hemostasis. Secondary Outcome Measures : Success in achieving hemostasis after application Estimated intraoperative blood loss Procedure duration Time in specialty units Length of hospital stay Incidence of adverse events. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2005 Clinical Trials

7659. Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures

from gastrointestinal, pulmonary, mouth/throat, genito-urinary tract, or central nervous system sites (excludes guaiac positive stool sample without gross blood or melena, minor epistaxis, minor gum bleeding, microscopic hematuria, superficial bruises, normal menses, or minor vaginal spotting) Pediatric patients requiring sedation in order to undergo a post-procedure ultrasound examination Already received FFP in the 24 hours before the planned invasive procedure Contacts and Locations Go (...) : Massachusetts General Hospital Collaborators: National Heart, Lung, and Blood Institute (NHLBI) Transfusion Medicine/Hemostasis Clinical Research Network Information provided by (Responsible Party): Massachusetts General Hospital Study Details Study Description Go to Brief Summary: This study will compare patients with mild to moderate prolongation of the INR test who receive FFP infusions prior to invasive hepatobiliary procedures for bleeding complications to patients who do not receive FFP infusions

2005 Clinical Trials

7660. Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers

Kong ClinicalTrials.gov Identifier: Other Study ID Numbers: NNH Study First Posted: September 12, 2005 Last Update Posted: August 17, 2017 Last Verified: August 2017 Keywords provided by Francis KL Chan, Chinese University of Hong Kong: Non-NSAID Non-Hp Bleeding Peptic Ulcer Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases (...) : During the observation period ] Hematemesis or melena documented by the admitting physician, or a decrease in the hemoglobin level of at least 2 g/dL, with ulcers or bleeding erosions confirmed on endoscopy. Secondary Outcome Measures : All-cause mortality [ Time Frame: During the observation period ] The secondary endpoint is recurrent lower gastrointestinal (GI) bleeding, which was defined as recurrent overt bleeding (melena or hematochezia without an upper GI source) or a drop in hemoglobin >2 g

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>